Clinical TrialMay 5, 2026, 08:36 AM
Ocugen OCU410 Phase 2 GA trial shows 31% lesion reduction; $115M notes
AI Summary
Ocugen announced positive 12-month data from its OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy, demonstrating a statistically significant 31% reduction in lesion size and 27% EZ preservation. The company also completed enrollment for its OCU400 Phase 3 trial for retinitis pigmentosa and OCU410ST Phase 2/3 trial for Stargardt disease, targeting BLA submissions by 2027. Additionally, Ocugen reported Q1 2026 financial results and closed a $115 million private offering of convertible senior notes, which is expected to extend its cash runway into 2028 and facilitate the retirement of $32.7 million in existing debt.
Key Highlights
- OCU410 Phase 2 GA trial showed a statistically significant 31% reduction in lesion size and 27% EZ preservation (p<0.05).
- Approximately 20% of OCU410 treated subjects demonstrated no disease progression; 75% showed >30% reduction in lesion growth.
- Ocugen completed a $115 million private offering of 6.75% convertible senior notes due 2034.
- The offering is expected to extend the company's cash runway into 2028.
- Ocugen plans to use $32.7 million of the net proceeds to retire existing Avenue debt with a 12.5% interest rate.
- Q1 2026 net loss was $(19.177) million, or $(0.06) per common share.
- Total operating expenses for Q1 2026 were $19.4 million, up from $16.0 million in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $32.2 million as of March 31, 2026, projected to be $112.1 million post-offering.